Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer : Update Bulletin # 2 [April 2019]

Product Code:
596201076
Publication Date:
April 2018
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Bristol-Myers Squibb announcing positive interim data from the CheckMate 650 assessing Opdivo (nivolumab) and Yervoy (ipilimumab) in metastatic castration-resistant prostate cancer (mCRPC); Janssen presenting preliminary data from the Phase II GALAHAD study assessing niraparib in patients with mCRCP at the American Society of Clinical Oncology Genitourinary Cancers Symposium (14-16 February 2019) In San Francisco, CA, USA; Onoclogy Ventures announcing that the first patient had been dosed in a Phase II study of LiPlaCis, its liposomal formulation of cisplatin.

Business Questions:

  • What are the experts' reactions to the data from Opdivo and Yervoy's Phase II trial in mCRPC?
  • How do the KOLs envisage Opdivo and Yervoy to be utilised in the treatment of prostate cancer?
  • What was the KOLs opinion on the preliminary data from the Phase II GALAHAD trial?
  • Where in the treatment paradigm could niraparib be utilised if approved?
  • What potential has the liposomal cisplatin product LiPlaCis have in the treatment of prostate cancer?
  • What potential patient population could LiPlaCis be used in, and what role will biomarker testing play?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved